A phase II randomised prospective study comparing Interleukin-2 versus Interleukin-2 with SRL 172 in patients with Advanced Renal Cell Carcinoma.

Trial Profile

A phase II randomised prospective study comparing Interleukin-2 versus Interleukin-2 with SRL 172 in patients with Advanced Renal Cell Carcinoma.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs IMM-201 (Primary) ; Interleukin-2
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Feb 2016 United Kingdom Clinical Research Network reports accrual to date as 46%.
    • 12 Feb 2016 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network record.
    • 18 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top